On our screens:Quality at a reasonable price
Is the price fair?
What ITGR's price assumes
Integer Holdings Corporation trades at 31.6× earnings against 30.9× for the median Medical Devices name, more expensive than its own group.
31.6
Trailing P/E · Medical Devices median 30.9 · 1.02× the median: the market pays up for this one
- Price / sales
- 1.61
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.2%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered +85% a year over the last three.
Details›
- Price / book2026-Q1
- 1.76
- EV / EBIT2026-Q1
- 20.8
- EV / sales2026-Q1
- 2.28
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $100M
- Market capitalisation
- $3.16B
- 3-year revenue growth
- +9.9%
- 3-year free cash flow growth
- +85%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $125.12 |
| Its own P/E history, median | $145.42 |
| Its own P/E history, upper quartile | $155.21 |
| 52-week range | $63.32 – $126.44 |
| Today | $126.34 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.